Efficacy and tolerance of liposomal daunorubicin in Kaposi sarcoma associated with human immunodeficiency virus infection [3]

Archives of Dermatology

Volumn 133, Issue 7, 1997, Pages 918-919

  Fournier, S ^a   Dupont, B ^a   Pialoux, G ^a   Eliaszewics, M ^a   Gonzales Canali, G ^a   Feuillie, V ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DAUNORUBICIN; LIPOSOME;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALOPECIA; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LETTER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN CANCER; TREATMENT OUTCOME;

EID: 0030851370     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.133.7.918     Document Type: Letter

References (4)